Evidence map›Paper›PMID 21370102›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2011

Omics-based molecular target and biomarker identification.

Zhang-Zhi Hu, Hongzhan Huang, Cathy H Wu, Mira Jung, Anatoly Dritschilo, Anna T Riegel, Anton Wellstein

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Biomarkers for Allogeneic HCT Outcomes.Frontiers in immunology · 2020
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Zhang-Zhi HuLombardi Cancer Center, Georgetown University, Washington, DC, USA. zh9@georgetown.edu
Hongzhan Huang
Cathy H Wu
Mira Jung
Anatoly Dritschilo
Anna T Riegel
Anton Wellstein
Georgetown University · USUniversity of Delaware · USGeorgetown University Medical Center · US

Funding

The UniProt protein sequence and function knowledgebaseU01HG002712 · NHGRI · EUROPEAN MOLECULAR BIOLOGY LABORATORY · PI APWEILER, ROLF · 2002 to 2009
$44.3M
THYMIDINE KINASE AND BRAIN TUMOR RADIATION RESISTANCEP01CA074175 · NCI · GEORGETOWN UNIVERSITY · PI DRITSCHILO, ANATOLY · 1997 to 2006
$13.2M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
Role of AIB1 in malignant progressionR01CA113477 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2005 to 2015
$2.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P01 CA074175NCI NIH HHS P01CA074175NCI NIH HHS R01 CA113477NCI NIH HHS T32 CA009686NHGRI NIH HHS U01 HG002712NHGRI NIH HHS U01-HG02712PHS HHS 261200800001E
6 · The paper itself

Abstract

Genomic, proteomic, and other omic-based approaches are now broadly used in biomedical research to facilitate the understanding of disease mechanisms and identification of molecular targets and biomarkers for therapeutic and diagnostic development. While the Omics technologies and bioinformatics tools for analyzing Omics data are rapidly advancing, the functional analysis and interpretation of the data remain challenging due to the inherent nature of the generally long workflows of Omics experiments. We adopt a strategy that emphasizes the use of curated knowledge resources coupled with expert-guided examination and interpretation of Omics data for the selection of potential molecular targets. We describe a downstream workflow and procedures for functional analysis that focus on biological pathways, from which molecular targets can be derived and proposed for experimental validation.

Indexed as

AnimalsBiomarkersComputational BiologyData Interpretation, StatisticalData MiningHumansInformation ManagementLiterature, ModernMiceMolecular Sequence AnnotationPhenotypeProtein Interaction MappingRatsSoftwareBiomarkers

Identifiers

PMID21370102
PMCPMC3742302
OpenAlexW1534341432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.